Disease-Modifying Antirheumatic Drug (DMARD) Market is Driven by Rising Prevalence of Arthritis
Wilmington, Delaware, United States, Transparency Market Research Inc. – Disease-modifying antirheumatic drugs (DMARDs) are a class of drugs utilized as a therapy for inflammatory arthritis, including psoriatic arthritis (PsA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS). They are also indicated for the treatment of other disorders such as connective tissue disease including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjogren syndrome (SS), along with the treatment of vasculitis, uveitis, inflammatory myositis, inflammatory bowel disease, etc.
The disease-modifying antirheumatic drug (DMARD) market can be segmented based on drug type, distribution channel, route of administration, indication, and region. Based on drug type, the disease-modifying antirheumatic drug (DMARD) market can be classified into Synthetic (sDMARD), Targeted synthetic DMARDs (tsDMARDs), Biological DMARDs (bDMARD) and others.
The Synthetic (sDMARD) segment can be further sub-segmented into Conventional synthetic (csDMARDs) sub-segment, which can be further split into Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine and gold salts. While the Biological DMARDs (bDMARD) segment can be further categorized into Original DMARDs (boDMARDs) and Biosimilar DMARDs (bsDMARDs).
The Biosimilar DMARDs (bsDMARDs) sub-segment can be split into primary, secondary & tertiary. Based on indication, the market can be categorized into ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus, and others. In terms of distribution channel, the market can be split into hospital pharmacies, retail pharmacies, and e-commerce. In terms of route of administration, the disease-modifying antirheumatic drug (DMARD) market can be segregated into oral, parenteral, and others.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45015
Key Drivers, Restraints, and Opportunities of Global Disease-Modifying Antirheumatic Drug (DMARD) Market
Launch of novel biosimilar, rising prevalence of arthritis, and an increase in the acceptance of biopharmaceuticals are major factors fueling the disease-modifying antirheumatic drug market. Furthermore, raising burden of rheumatoid arthritis disease coupled with a rise in geriatric population is also driving the market. Arthritis generally impacts the geriatric population, and the prevalence is observed higher in females. Thus, larger cases of this disease could be observed in the geriatric population, which is further boosting the market.
Various medication are being developed for the treatment of rheumatoid arthritis since the last few years. Thus, an increase in alternatives and awareness about safer drugs are further driving the global disease-modifying antirheumatic drug market.
Moreover, enhanced diagnostic procedures are also boosting the global market for disease-modifying antirheumatic drugs. Additionally, the market is anticipated to expand due to the transmission of several awareness programs and a rise in number of skilled healthcare professionals. In 2017, AbbVie Inc. was a leader in the global disease-modifying antirheumatic drugs market. Nevertheless, various leading companies are focused on investing on research and development of novel medicines in consolidate their presence in the market.
Asia Pacific to Capture Major Share of Global Disease-Modifying Antirheumatic Drug (DMARD) Market
The market in Asia Pacific is anticipated to expand at a significant growth rate during the forecast period, owing to rising healthcare expenditure. However, the lower cost of manufacturing in China and India has resulted in an increase in manufacturing facilities, attracting numerous pharmaceutical and biotechnological companies to Asia Pacific.
Rise in cases of rheumatoid arthritis disease is also estimated to fuel the market in the region during the forecast period. For instance, as per the statistics of Institute for Health Metrics and Evaluation, the cases of rheumatoid arthritis have increased from 183,272 in 2007 to 263,365 in 2017 only in India. Thus, observing the number of cases in other significant countries of Asia Pacific, the healthcare activities concerned with the treatment of rheumatoid arthritis would require continuous support from everyone.
North America follows Asia Pacific in terms of share of the global market. The market in the region is expected to expand at a higher growth rate during the forecast period owing to an increase in research and development activities toward the development of novel therapies for rheumatoid arthritis. Moreover, the presence of leading industry players is also projected to fuel the market in the region.
Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=45015
Key Players Operating in Global Disease-Modifying Antirheumatic Drug (DMARD) Market
The global disease-modifying antirheumatic drug (DMARD) market is highly fragmented, with the presence of various key players. A large number of manufacturers hold a major share in their respective regions. Major players operating in the global disease-modifying antirheumatic drug (DMARD) market are:
- Sanofi SA
- Pfizer Inc.
- F. Hoffman-La Roche AG
- Johnson & Johnson
- AbbVie Inc.
- Eli Lilly & Company
- Amgen Inc.
- Sobi Inc.
- Bristol-Myers Squibb Company
- UCB S.A.
More Trending Reports by Transparency Market Research –
Women Intimate Care Market: The global women intimate care market is estimated to register growth at a CAGR of 5% during the forecast period of 2022 to 2031.
Cat Allergy in Humans Market: The global cat allergy in humans market is anticipated to exceed US$ 7.8 Bn by 2031. The global market is projected to grow at a CAGR of 6.3% from 2022 to 2031.
Dermal Filler Market: The dermal filler market in the U.S. is anticipated to reach US$ 3.3 Bn by the end of 2031. The market in the country is projected to expand at a CAGR of 10.9% from 2022 to 2031.
Particle Therapy Market: The global particle therapy market is anticipated to exceed the value of US$ 1.2 Bn by 2031. The global market is projected to expand at a CAGR of 8.6% from 2022 to 2031.
Physician Dispensed Cosmeceuticals Market: The global physician dispensed cosmeceuticals market is expected to reach the value of US$ 19 Bn by the end of 2031.
Hernia Repair Devices Market: The global hernia repair devices market is expected to reach the value of US$ 8.62 Bn by the end of 2028.
Preventive Healthcare Technologies & Services Market: The global preventive healthcare technologies and services market is expected to reach the value of US$ 557.47 Mn by the end of 2028.
Coronary Stents Market: The global coronary stents market is expected to reach the value of US$ 25.7 Bn by the end of 2028.
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
USA – Canada Toll Free: 866-552-3453